Waypoint Capital is the Geneva-based family office of Ernesto Bertarelli, the Swiss-Italian billionaire whose family built Serono into one of the world’s largest biotechnology companies before selling it to Merck KGaA for $13.3 billion in 2007. The family office manages an estimated $10 billion in assets across a diversified portfolio.
Investment Strategy
Waypoint Capital invests across private equity, venture capital, life sciences, real estate, and public markets, with a distinctive emphasis on healthcare and biotechnology reflecting the Bertarelli family’s deep expertise in the sector. The family office makes both direct investments and fund commitments, maintaining flexibility to deploy capital across the spectrum from early-stage venture to mature buyout opportunities.
The life sciences portfolio is a defining feature of Waypoint Capital’s strategy. The family’s decades of experience building and operating Serono provides institutional-quality insight into drug development, regulatory processes, and commercialization strategies. This expertise is valuable both for direct investments in biotech companies and for evaluating fund managers in the healthcare space.
Beyond healthcare, Waypoint Capital invests in technology, consumer brands, and financial services. The family office also maintains significant real estate holdings in Switzerland, London, and other European markets. Ernesto Bertarelli’s passion for sailing and ocean conservation has led to investments in marine technology and sustainability, supported by the Bertarelli Foundation’s scientific research programs.
How to Approach
Fund managers seeking Waypoint Capital commitments should recognize the family office’s strong preference for healthcare, life sciences, and technology investments. Managers with demonstrated expertise in biotech, medtech, or pharmaceutical services will find natural alignment. The Geneva base means European managers have proximity advantages, though Waypoint invests globally. The family values deep sector expertise, strong management relationships, and strategies that align with their long-term, research-driven investment philosophy.
Frequently Asked Questions
What is Waypoint Capital's origin?
Waypoint Capital was established by Ernesto Bertarelli following the $13.3 billion sale of Serono, his family's biotechnology company, to Merck KGaA in 2007. The family office manages the Bertarelli family's wealth from Geneva, investing across private equity, venture capital, life sciences, real estate, and public markets.
Does Waypoint Capital focus on life sciences investing?
Yes. Given the Bertarelli family's heritage in biotechnology (Serono was one of the world's largest biotech companies), Waypoint Capital maintains a strong focus on life sciences and healthcare investing. The family office invests in biotech and pharma companies both directly and through fund commitments, leveraging deep industry knowledge and networks built over decades in the sector.
What other sectors does Waypoint Capital invest in?
Beyond life sciences, Waypoint Capital invests in technology, consumer, financial services, and real estate. The family office also supports Ernesto Bertarelli's passion for sailing (he won the America's Cup twice with Alinghi) and marine conservation through the Bertarelli Foundation, which funds ocean research and protection initiatives.
